NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Although you are right no2Koolaid, bear in mind that the first release of part of the data was included in the recent presentations and not yet in a JA. While the first JA may be one of several to follow, it has to minimally include in addition to the already detailed release of the OS results of the treatment group, the entire data pertaining to the OS of the 64 crossovers and the 35 permanent placebos.
Much of the OS results up to 24 months pertaining to those two smaller arms, can already be calculated by utilizing the following.
1. The OS of the 331 patients at 12 and 24 months from randomization (15 and 27 months from surgery) displayed in fig. 2 of the 2018 JTM publication
2. The OS of the the 232 treatment patients at 12 and 24 months from randomization ( OS graph of the 232 treatment patients) shown in the May 10, NYAS presentation.
3. The information in the NYAS presentation that 6 months after progression 90.6% of the cross over patients were still alive.

From those three sources it is easy to calculate that the mOS of the 99 placebos was around 24 months, that the mOS of the 35 permanent placebos in that group of 99 was below 12 months and that the mOS of the 64 crossovers was therefore several months longer than 24 months.

Since in addition to the recent presentation data, so much survival data concerned with the 99 placebos can already be estimated fairly accurately, there is no longer any reason for not presenting in the upcoming JA, the complete survival data that pertains to the remaining 99 patients. i